Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,100 shares of the biopharmaceutical company’s stock after buying an additional 8,400 shares during the quarter. Regeneron Pharmaceuticals comprises 2.2% of Rhenman & Partners Asset Management AB’s holdings, making the stock its 11th largest position. Rhenman & Partners Asset Management AB’s holdings in Regeneron Pharmaceuticals were worth $20,298,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Osaic Holdings Inc. raised its position in Regeneron Pharmaceuticals by 55.2% in the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after purchasing an additional 6,073 shares during the period. Robeco Institutional Asset Management B.V. increased its position in shares of Regeneron Pharmaceuticals by 153.4% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after purchasing an additional 73,176 shares during the last quarter. PGGM Investments raised its holdings in Regeneron Pharmaceuticals by 9.7% in the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock valued at $52,057,000 after buying an additional 8,187 shares during the period. Rakuten Investment Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $33,121,000. Finally, Sound Shore Management Inc CT acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $64,677,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This represents a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 5,274 shares of company stock valued at $4,142,738. Company insiders own 7.02% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of several research analyst reports. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Guggenheim upped their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, HSBC initiated coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $255.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $759.82 on Friday. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The firm has a market cap of $80.33 billion, a PE ratio of 18.28, a price-to-earnings-growth ratio of 2.04 and a beta of 0.41. The company’s 50 day moving average is $770.81 and its two-hundred day moving average is $688.75.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the firm posted $12.07 earnings per share. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.